About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

IGF-1 Therapy in Patients With Cystic Fibrosis

NCT00566241·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Stony Brook University

28 week, double blind, cross over study to determine the efficacy of rhIGF-1 on body weight and body composition in patients with cystic fibrosis.

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Diagnosis of cystic fibrosis as proven by either sweat chloride or DNA analysis.
Age \>= 18 yr.
Tanner stage: Femake Breasts: 4-5 Male Genitalia: 4-5

You may not be if

Hemoglobin A1C \> 8.5 %
Diabetic retinopathy
Obstructive sleep apnea
Respiratory failure requiring mechanical ventilation.
Status post pulmonary transplantation.
Concurrent or recent (within past 6 months) receipt of human growth hormone.
History of adverse side effects to growth hormone other than carbohydrate intolerance.
Pregnancy or attempting pregnancy.
Women who are breast feeding.
Sexually active women who refuse to use or are incapable of responsibly using reliable contraception.
Proven non compliance with medical regimens.
Inability or refusal to take subcutaneous injections.
Known allergy to components in the IGF-I preparation.

The record

StatusTerminated

PhasePhase 1

Taking part15

StartedJun 2008

UpdatedJan 28, 2013

Conditions

Cystic Fibrosis

Where1

State University of New York
Stony Brook, New York, United States